Additional Information
Market: ASX
Sector: Pharmaceuticals & Biotechnology
Latest Price: A$0.19  (8.57% Ascending)
52-week High: A$0.83
52-week Low: A$0.08
Market Cap: A$50.22M
1 year chart
Deal ISN Tax Free*
*subject to change and depends on individual circumstances.
1 day chart

Add to watchlist:

Only registered members can add into watchlist !

Register here !
iSonea Limited
Deal iSonea Limited Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

iSonea (ASX: ISN), formerly KarmelSonix, is a global leader in developing acoustic respiratory monitoring devices, the Company’s ground breaking products are based on acoustic signal acquisition technology and advanced analysis capabilities. 


The company’s proprietary technology responds to an unmet need for accurate, low...

Read more

iSonea expands board expertise with new director appointments

April 04 2012, 1:17am

iSonea (ASX: ISN) has welcomed two new directors to the board with the appointment of Dr Ross Macdonald and Dr Stewart Washer.

The company has also appointed Donal O’Dwyer as a special advisor to the board.

Macdonald and Washer replace Paul Hopper and Fabio Pannuti who have stepped down as directors.

Macdonald has extensive local and international biomedical experience in general management, technology commercialisation, capital raising, and business development, including licensing, mergers and acquisitions.

He was formerly managing director and chief executive officer of Living Cell Technologies (ASX: LCT; OTCQX: LVCLY), a development stage biotechnology company focused on therapeutics for type-1 diabetes, Parkinson’s disease, and stroke.

He is currently a Member of the Investment Committee of Uniseed Management, a venture fund established to commercialise research outcomes from the Universities of Queensland, Melbourne and New South Wales.

Macdonald also serves as a director for pharmaceutical development companies Telesso Technologies (ASX: TEO)and Hatchtech.

Previously, Macdonald was vice president, business development for Sinclair Pharmaceuticals, vice president of corporate development for Stiefel Laboratories, and vice president of business development for Connetics Corporation when it was acquired by Stiefel. 

He was also vice president of research and development for Australia’s largest and oldest pharmaceutical company, F.H. Faulding & Co. 

Washer has 15 years of senior executive and board experience at medical device, drug development and agrifood companies. 

He was a venture partner with Inventages, a Nestlé fund and is currently investment manager with IB Managers, which manages Australian life science funds. 

Washer was previously chief executive officer of Calzada (ASX: CZD), the founding chief executive officer ofPhylogica (ASX: PYC), chief executive officer of Celentis, and managed the commercialisation of intellectual property from AgResearch in New Zealand.

He has held a number of board positions, including chairman of Resonance Health (ASX: RHT) and Hatchtech, and director of iCeutica and AusBiotech. 

He is currently a director of Healthlinx (ASX: HTX) and Immuron (ASX: IMC).

Meanwhile, O’Dwyer has extensive worldwide sales, marketing, product development and manufacturing operations experience in the healthcare products and medical device industries. 

He was formerly worldwide president of Cordis Cardiology, a Johnson & Johnson company, during which time he re-established their position as a leader in international cardiology with the development and launch of the revolutionary Cypher coronary stent. 

He oversaw the growth of that business from US$500 million per annum to over US$2 billion per annum.

O’Dwyer is currently deputy chairman at Mesoblast (ASX: MSB; OTC ADR: MBLTY), a leading developer of biological products for regenerative medicine, and a member of the board at global hearing solution company Cochlear. 

Previously, he was president of the Cardiovascular Group, Europe for Baxter Healthcare. He was also chairman of AtCor Medical and has served as director at Angioblast Systems and Sunshine Heart.

Mike Thomas, chief executive officer, said:

“We are excited to gain the extensive expertise and insights that Dr Ross Macdonald and Dr Stewart Washer will bring to the commercialisation opportunities that lie ahead for us, as iSonea achieves significant milestones and introduces innovative medical devices and mobile health solutions to the world’s key markets for asthma and other respiratory disorders.”

iSonea recently reached an important milestone with the start of its first large U.S. post-market study of its WheezoMeter™ monitoring device in paediatric patients with a range of asthma symptom severity.    

The study will include patients who are too young to be tested with spirometry, a traditional measuring technique used in older children and adults. 

The WheezoMeter™ has the potential to meet a critical unmet need for better, easy to use monitoring tools for young asthma patients. 

Advance towards commercialisation 

iSonea is preparing to roll out a number of its asthma products over the next 24 months after entering its first formal partnership with telecommunications company Qualcomm Life for the development of a mobile asthma monitoring platform. 

The new technology will combine iSonea’s proprietary Acoustic Respiratory Monitoring (ARM) ™ devices and mobile health asthma management systems with Qualcomm’s 2net™ platform. 

iSonea will leverage Qualcomm's 2net Hub technology, a plug-and-play connectivity gateway to the cloud-based 2net Platform data server, to collect and transmit patient health data from its asthma monitoring devices. 

Importantly, the partnership will also provide iSonea with a larger scale, lower cost platform.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.